{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:38:20Z","timestamp":1790307500912,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1093\/eurheartj\/ehs083","type":"journal-article","created":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T00:44:51Z","timestamp":1334623491000},"page":"2151-2162","source":"Crossref","is-referenced-by-count":32,"title":["Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study"],"prefix":"10.1093","volume":"33","author":[{"given":"Yongwhi","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Hoon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udaya S.","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hwa","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Jung","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Rang","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Jae","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Ha","family":"Gho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P.","family":"Bliden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choong Hwan","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yong","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunjoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,4,16]]},"reference":[{"key":"key\n\t\t\t\t20170515130734_EHS083C1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jacc.2007.10.002","article-title":"2007 focused update of the ACC\/AHA\/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology\/American Heart Association Task Force on Practice guidelines","volume":"51","author":"ACC\/AHA\/SCAI","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130734_EHS083C2","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIR.0b013e31820f2f3e","article-title":"2011 ACCF\/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina\/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"123","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515130734_EHS083C3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Working Group on High On-Treatment Platelet Reactivity","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130734_EHS083C4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/0091270009343005","article-title":"Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans","volume":"50","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170515130734_EHS083C5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite","volume":"38","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t20170515130734_EHS083C6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3909\/ricm0590","article-title":"The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors","volume":"12","year":"2011","journal-title":"Rev Cardiovasc Med"},{"key":"key\n\t\t\t\t20170515130734_EHS083C7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jcin.2010.12.009","article-title":"Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations","volume":"4","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20170515130734_EHS083C8","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1007\/s11095-006-9084-4","article-title":"Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4","volume":"23","year":"2006","journal-title":"Pharm Res"},{"key":"key\n\t\t\t\t20170515130734_EHS083C9","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2174\/138161206776361354","article-title":"Thienopyridines and statins: assessing a potential drug-drug interaction","volume":"12","year":"2006","journal-title":"Curr Pharm Des"},{"key":"key\n\t\t\t\t20170515130734_EHS083C10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/dmd.104.002477","article-title":"Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1","volume":"33","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t20170515130734_EHS083C11","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s11095-005-9371-5","article-title":"Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport","volume":"23","year":"2006","journal-title":"Pharm Res"},{"key":"key\n\t\t\t\t20170515130734_EHS083C12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000047060.60595.CC","article-title":"Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction","volume":"107","year":"2003","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515130734_EHS083C13","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2010.11.024","article-title":"Clopidogrel-drug interactions","volume":"57","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130734_EHS083C14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FJC.0b013e3181ffe8d0","article-title":"The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity","volume":"57","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"key\n\t\t\t\t20170515130734_EHS083C15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.111.184895","article-title":"Dissecting the activation of thienopyridines by cytochrome P450s using a pharmacodynamic assay in vitro","volume":"339","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20170515130734_EHS083C16","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.jacc.2005.07.041","article-title":"Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study","volume":"46","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130734_EHS083C17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11239-010-0484-2","article-title":"Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y(12) assay","volume":"30","year":"2010","journal-title":"J Thromb Thrombolysis"},{"key":"key\n\t\t\t\t20170515130734_EHS083C18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jcin.2010.05.007","article-title":"Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg\/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study","volume":"3","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20170515130734_EHS083C19","article-title":"Primary Results From Genotype Information and Functional Testing (GIFT): A Prospective Pharmacogenomic Analysis of Clopidogrel Therapy","year":"2011"},{"key":"key\n\t\t\t\t20170515130734_EHS083C20","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/hrt.2010.220509","article-title":"Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting","volume":"97","year":"2011","journal-title":"Heart"},{"key":"key\n\t\t\t\t20170515130734_EHS083C21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/clpt.2011.132","article-title":"Guidelines for cytochrome P450\u20132C19 (CYP2C19) genotype and clopidogrel therapy","volume":"90","author":"Clinical Pharmacogenetics Implementation Consortium","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20170515130734_EHS083C22"},{"key":"key\n\t\t\t\t20170515130734_EHS083C23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/clpt.2010.316","article-title":"Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions","volume":"89","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20170515130734_EHS083C24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/01.CIR.0000112378.09325.F9","article-title":"Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance","volume":"109","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515130734_EHS083C25","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2174\/138920008786049302","article-title":"Clinical pharmacogenetics and potential application in personalized medicine","volume":"9","year":"2008","journal-title":"Curr Drug Metab"},{"key":"key\n\t\t\t\t20170515130734_EHS083C26","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515130734_EHS083C27","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","article-title":"Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome","volume":"57","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130734_EHS083C28","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2217\/pgs.11.73","article-title":"Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention","volume":"12","year":"2011","journal-title":"Pharmacogenomics"},{"key":"key\n\t\t\t\t20170515130734_EHS083C29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20170515130734_EHS083C30","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000088780.57432.43","article-title":"Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial","volume":"108","author":"Clopidogrel for the Reduction of Events During Observation Investigators","year":"2003","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515130734_EHS083C31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacc.2007.01.097","article-title":"Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial","volume":"50","author":"CHARISMA Investigators","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130734_EHS083C32","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/MOL.0b013e32833b776c","article-title":"Do structural differences in statins correlate with clinical efficacy?","volume":"21","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"key\n\t\t\t\t20170515130734_EHS083C33","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/ATVBAHA.108.183160","article-title":"Antiplatelet actions of statins and fibrates are mediated by PPARs","volume":"29","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20170515130734_EHS083C34","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"PLATO investigators","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515130734_EHS083C35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.tpj.6500413","article-title":"ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research","volume":"7","year":"2007","journal-title":"Pharmacogenomics J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/33\/17\/2151\/17050162\/ehs083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T09:09:20Z","timestamp":1713863360000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/10.1093\/eurheartj\/ehs083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,16]]},"references-count":35,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2012,4,16]]},"published-print":{"date-parts":[[2012,9]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehs083","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,16]]}}}